Drug Sales Trends for APRISO

Annual Sales Revenues and Units Sold for APRISO

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
APRISO			2021
APRISO			2020
APRISO			2019
APRISO			2018
APRISO			2017

Market Analysis and Sales Projections for Apriso

Overview of Apriso

Apriso, also known as mesalamine, is an aminobenzoic acid derivative that acts as an anti-inflammatory agent. It is formulated as an extended-release hard gelatin capsule for oral administration and is indicated for the induction and maintenance of remission in ulcerative colitis[1].

Market Context: Inflammatory Bowel Diseases (IBD)

The global inflammatory bowel diseases (IBD) drug market is a significant sector, with a market size estimated at $7.2 billion in 2018. Biologic therapies dominate this market, holding a 65% share and projected to grow at a CAGR of 3.6% in the initial part of the forecast period[4].

Competitive Landscape

Apriso competes within the aminosalicylates segment of the IBD market, which includes other notable drugs such as Asacol, Lialda, and Pentasa. The competitive landscape is further complicated by the presence of biologics, immunomodulators, and other drug classes that also treat IBD[4].

Sales Performance and Trends

Historically, Apriso has been a stable performer in the IBD market. However, the approval of generic versions can impact its sales. A generic version of Apriso has been approved by the FDA, although its commercial availability may be delayed due to drug patents and exclusivity[3].

Revenue Forecasts

Revenue forecasts for Apriso and similar drugs are typically included in broader IBD market reports. For instance, the global IBD drug market report provides revenue forecasts from 2019 to 2029, segmented by drug class, indication, and distribution channel. While specific figures for Apriso are not detailed here, the overall IBD market is expected to grow, driven by increasing demand for effective treatments[4].

Impact of Generic Competition

The approval of a generic version of Apriso could significantly impact its sales. Generic competition often leads to a decline in sales for the branded drug as generics are typically cheaper and can capture a substantial portion of the market share. However, the extent of this impact depends on factors such as the timing of the generic launch and the brand's loyalty among patients and prescribers[3].

Market Segmentation

The IBD drug market is segmented by drug class, indication, and distribution channel. Apriso falls under the aminosalicylates category, which is one of the traditional and well-established segments. The market is also segmented geographically, with key markets including the US, Japan, and emerging markets. The US and European markets are particularly significant for Apriso due to the high prevalence of IBD and the drug's established presence in these regions[4].

Financial Performance of Similar Drugs

To gauge the potential financial performance of Apriso, it is useful to look at the financial performance of similar drugs and the overall pharmaceutical companies involved in the IBD market. For example, AstraZeneca's financial reports show strong growth in therapy areas relevant to IBD, such as gastrointestinal diseases, although Apriso itself is not specifically highlighted in these reports[2][5].

Net Present Value (NPV) Analysis

For a more detailed financial analysis, an NPV model can be used. GlobalData's NPV model for pharmaceutical assets, including drugs like Apriso, provides a comprehensive forecasting and valuation tool. This model includes a revenue model, patent expiry model, operating profit model, net profit calculation, and discounted cash flow analysis to derive the NPV. Such models are crucial for strategic decision-making around pharmaceutical assets[1].

Key Takeaways

• Market Size and Growth: The global IBD drug market is substantial and growing, with biologics dominating the market.
• Competitive Landscape: Apriso competes in a crowded market with other aminosalicylates and biologics.
• Generic Competition: The approval of a generic version of Apriso could significantly impact its sales.
• Revenue Forecasts: The overall IBD market is expected to grow, but specific forecasts for Apriso would require detailed market reports.
• NPV Analysis: Using an NPV model can provide a comprehensive financial analysis for strategic decision-making.

FAQs

1. What is Apriso used for? Apriso is used for the induction and maintenance of remission in ulcerative colitis.

2. What is the current market size of the IBD drug market? The global IBD drug market was estimated at $7.2 billion in 2018.

3. How does generic competition affect Apriso's sales? Generic competition can significantly reduce Apriso's sales as generics are cheaper and can capture a substantial market share.

4. What is the role of NPV analysis in evaluating pharmaceutical assets like Apriso? NPV analysis provides a comprehensive forecasting and valuation tool, including revenue models, patent expiry models, and discounted cash flow analysis, to help in strategic decision-making.

5. Which segments dominate the IBD drug market? Biologic therapies dominate the IBD market, holding a 65% share as of 2018.

Sources

1. GlobalData: "Net Present Value Model: Apriso" - Evaluating the value of drugs using NPV models.
2. AstraZeneca: "Q1 2024 results announcement" - Financial performance and growth in various therapy areas.
3. Drugs.com: "Generic Apriso Availability" - Approval and potential impact of generic versions.
4. Visiongain: "Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2019-2029" - Market size, growth, and segmentation.
5. AstraZeneca: "FY and Q4 2023 results announcement" - Financial performance and growth in key therapy areas.

Last updated: 2025-01-01